Marlborough, Mass.-based Boston Scientific Corp. is backing a venous stent maker to the tune of $25 million in equity financing, making it the largest investor in the company. The series D round is expected to enable St. Louis-based Veniti Inc. to complete a U.S. clinical trial of its Vici Venous Stent System.